MAPT and Alzheimer disease: Although neurofibrillary tangles constitute one of the main pathophysiological conditions of AD, some studies have shown that inhibition of neurofibrillary tangles alone cannot be a potential target; therefore, any therapeutic approach must be multi-targeted to make a real difference in the treatment of AD, and tau-targeted drugs often target amyloid plaques as well.[22,23]